NewslettersHematopoiesis News Pyrimidine Depletion Enhances Targeted and Immune Therapy Combinations in Acute Myeloid Leukemia By Noshin Noorjahan - April 24, 2024 0 Researchers introduced HOSU-53, a dihydroorotate dehydrogenase inhibitor with significant monotherapy activity, which was further enhanced when combined with other standard-of-care therapeutics. [JCI Insight] Full Article